“We are pleased with the strong confidence in IRLAB from both existing and new investors, which enables this capital raise to be carried out in today’s challenging market conditions. We are in an intensive phase with well-advanced dialogues with potential partners and active development work within our projects. By strengthening our financial resources, we create greater freedom of action and increase the opportunities for success in ongoing and future business discussions, with the goal of entering into at least one revenue-generating collaboration agreement during the current year. In addition, we gain the capacity to carry out activities that increase the attractiveness of our drug candidate IRL1117 while also reducing our loan financing. A fully subscribed rights issue and overallotment issue would mean that the company is fully financed into the fourth quarter of 2027, beyond the planned read-out of results in the ongoing clinical study with IRL757 in middle of 2027,” says Kristina Torfgård, CEO of IRLAB Therapeutics.

The Board of Directors has further resolved, conditional upon approval by the extraordinary general meeting and amendment of the articles of association, on an overallotment issue of up to approximately SEK 33.8 million.

The company has received subscription undertakings totalling approximately SEK 55 million, corresponding to approximately 81 percent of the Rights Issue, from the company’s major shareholders and a number of new professional investors. Together with received subscription intentions of approximately SEK 6.8 million, the Rights Issue is thus covered by a total of approximately SEK 61.8 million through subscription undertakings and subscription intentions corresponding to approximately 91 percent of the Rights Issue. In addition, the company announces that the term for SEK 18.5 million of the outstanding loan of approximately SEK 23.7 million from Fenja Capital is extended from 30 October 2026 to 30 November 2027. The remaining SEK 5.2 million shall be repaid in connection with the completion of the Rights Issue.